Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Idec/Elan Tysabri Clears FDA; Promotion Will Focus On Monotherapy

Executive Summary

Biogen Idec and Elan plan to promote the once-monthly multiple sclerosis therapy Tysabri primarily as first-line monotherapy to patients who have discontinued previous therapy

You may also be interested in...



Tysabri May Launch At Higher Price With Added Efficacy Data, RiskMAP Cost

Biogen Idec/Elan appear poised to market their re-approved multiple sclerosis therapy Tysabri (natalizumab) at a higher price than when it was first introduced

Tysabri May Launch At Higher Price With Added Efficacy Data, RiskMAP Cost

Biogen Idec/Elan appear poised to market their re-approved multiple sclerosis therapy Tysabri (natalizumab) at a higher price than when it was first introduced

Tysabri Re-Entry Hinges On Effective Risk Management: Diagnostics May Be Key

Any risk management program tied to the market re-entry of Biogen Idec/Elan's Tysabri would likely include diagnostic procedures to test for early signs of progressive multifocal leukoencephalopathy

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045020

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel